Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Liabilities and Shareholders Equity (2022 - 2026)

Lexeo Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $139.8 million for Q4 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 44.02% to $139.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $194.5 million, a N/A change, with the full-year FY2023 number at $139.8 million, up 44.02% from a year prior.
  • Liabilities and Shareholders Equity hit $139.8 million in Q4 2023 for Lexeo Therapeutics, up from $54.7 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for LXEO hit a ceiling of $139.8 million in Q4 2023 and a floor of $54.7 million in Q3 2023.